Sui generis: Gene therapy and delivery systems for the treatment of glioblastoma

Neuro-Oncology

Volumn 17, Issue , 2015, Pages ii24-ii36

  Kane, J Robert ^a   Miska, Jason ^a   Young, Jacob S ^a   Kanojia, Deepak ^a   Kim, Julius W ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

delivery vehicles; gene therapy; glioblastoma; immunomodulatory therapy; oncolytic virotherapy

Indexed keywords

ADENOVIRUS VECTOR; BEVACIZUMAB; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNX 2401; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GENE THERAPY AGENT; GOLD NANOPARTICLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HSV 1716; INTERLEUKIN 12; LIPOSOME; MACROGOL; MICRORNA; MULTI WALLED NANOTUBE; ONCOLYTIC VIRUS; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; SILVER NANOPARTICLE; THYMIDINE KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALPROIC ACID; VELEDIMEX; VOCIMAGENE AMIRETROREPVEC;

ADENO ASSOCIATED VIRUS 2; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; APOPTOSIS; BLOOD BRAIN BARRIER; BYSTANDER EFFECT; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CYTOTOXICITY; DENDRITIC CELL; DRUG RELEASE; GLIOBLASTOMA; H-1 PARVOVIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOMODULATORY GENE THERAPY; IMMUNOSURVEILLANCE; LIPOSOMAL GENE DELIVERY SYSTEM; MESENCHYMAL STEM CELL; MICELLE; NEURAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE THERAPY; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; ANIMAL; BRAIN NEOPLASMS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; PROCEDURES; THERAPEUTIC USE; TREATMENT OUTCOME; TRENDS; VIRUS;

ANIMALS; BRAIN NEOPLASMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; TREATMENT OUTCOME; VIRUSES;

EID: 84924545195     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou355     Document Type: Review

References (95)

1. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443-2449.
2. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40.
3. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025):949-955.
4. Fischer U, Steffens S, Frank S, et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005;24(7):1231-1243.
5. Kroeger KM, Muhammad AK, Baker GJ, et al. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med. 2010;10(53):293-304.
6. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11(17):2389-2401.
7. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010;290(1):58-67.
8. Kim SW, Kim SJ, Park SH, et al. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res. 2013;19(2):415-427.
9. McBride WH. Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma. Future Oncol. 2012;8(1):17-20.
10. Ryu CH, Park KY, Kim SM, et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem Biophys Res Commun. 2012; 421(3):585-590.
11. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
12. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011;13(1):3-13.
13. Wainwright DA, Dey M, Chang A, et al. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol. 2013;4:4116.
14. Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011;6(1):e16195.
15. Xu S, Shao QQ, Sun JT, et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol. 2013;15(9):1160-1172.
16. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13(7):2158-2167.
17. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615.
18. Maes W, Rosas GG, Verbinnen B, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol. 2009;11(5):529-542.
19. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20: 5290-5301.
20. Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803-2811.
21. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2): 343-349.
22. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3):469-479.
23. Badie B, Drazan KE, Kramar MH, et al. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res. 1995; 17(3):209-216.
24. Inoue R, Moghaddam KA, Ranasinghe M, et al. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther. 2004;11(15):1195-1204.
25. Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013;335(1):201-204.
26. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene. 2012;31(15):1884-1895.
27. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirusmediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21(13):2508-2518.
28. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7): 397-405.
29. Wang HY, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910-918.
30. Dmitrieva N, Yu L, Viapiano M, et al. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res. 2011;17(6):1362-1372.
31. Melcher A, Parato K, Rooney CM, et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011; 19(6):1008-1016.
32. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastomaderived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472-3481.
33. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 2012;18(1):69-81.
34. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther. 2011;19(6):1097-1106.
35. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5(8):881-887.
36. Nandi S, Lesniak MS. Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther. 2009;9(6):737-747.
37. Kim JW, Glasgow JN, Nakayama M, et al. An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer. PLoS One. 2013;8(2):e55533.
38. Jeong M, Kwon YS, Park SH, et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One. 2009;4(2):e4545.
39. Puntel M, Ghulam Muhammad AKM, Farrokhi C, et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol. 2013;268(3): 318-330.
40. Bowers G, He J, Schulz K, et al. Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9 l and RG2 models. Front Biosci. 2003;8:8a54-8a61.
41. Arafat WO, Buchsbaum DJ, Gomez-Navarro J, et al. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int J Radiat Oncol Biol Phys. 2003;55(4): 1037-1050.
42. Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther. 2010;18(2):285-294.
43. Gatson NN, Chiocca EA, Kaur B. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett. 2012;527(2): 62-70.
44. Ho IA, Ng WH, Lam PY. FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. Mol Cancer. 2010;9: 9270.
45. Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013;15(6):591-599.
46. Coura Rdos S, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J. 2007;4:499.
47. Ma HI, Hueng DY, Shui HA, et al. Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation. Int J Mol Sci. 2014;15(3):4393-4414.
48. Ma HI, Lin SZ, Chiang YH, et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 2002;9(1): 2-11.
49. Matsuda M, Yamamoto T, Matsumura A, et al. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Ther. 2009;16(12): 1465-1476.
50. Yamanaka R, Tsuchiya N, Yajima N, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg. 2003; 99(4):746-753.
51. Timiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med. 2001;3(5):468-477.
52. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997;3(4):437-442.
53. Mitra S, Gaur U, Ghosh PC, et al. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001;74(1-3): 317-323.
54. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:141-116.
55. Frieboes HB, Wu M, Lowengrub J, et al. A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS One. 2013;8(2):e56876.
56. Orza A, Soritau O, Tomuleasa C, et al. Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine. 2013;8:8689-8702.
57. Wang CH, Chiou SH, Chou CP, et al. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine. 2011;7(1):69-79.
58. Zhang Y, Bai Y, Yan B. Functionalized carbon nanotubes for potential medicinal applications. Drug Discov Today. 2010; 15(11-12):428-435.
59. Gao JQ, Lv Q, Li LM, et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013;34(22):5628-5639.
60. Eavarone DA, Yu X, Bellamkonda RV. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res. 2000;51(1):10-14.
61. Ananda S, Nowak AK, Cher L, et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011;18(11):1444-1448.
62. Yang ZZ, Li JQ, Wang ZZ, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226-5239.
63. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 2000;97(23): 12846-12851.
64. Yuan SH, Martin J, Elia J, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One. 2011;6(3):e17540.
65. Reitz M, Demestre M, Sedlacik J, et al. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med. 2012;1(12):866-873.
66. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262-278.
67. Young JS, Kim JW, Ahmed AU, et al. Therapeutic cell carriers: a potential road to cure glioma. Expert Rev Neurother. 2014;14(6): 651-660.
68. Balyasnikova IV, Ferguson SD, Han Y, et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Letters. 2011;310(2):148-159.
69. Hingtgen S, Ren X, Terwilliger E, et al. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther. 2008;7(11):3575-3585.
70. Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013;5(184):184ra159.
71. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41-49.
72. Choi SA, Hwang SK, Wang KC, et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol. 2011;13(1):61-69.
73. Chang DY, Yoo SW, Hong Y, et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer. 2010;127(8): 1975-1983.
74. Lee DH, Ahn Y, Kim SU, et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 2009;15(15):4925-4934.
75. Honasoge A, Sontheimer H. Involvement of tumor acidification in brain cancer pathophysiology. Front Physiol. 2013;4:4316.
76. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128-E147.
77. Li Y, He H, Jia X, et al. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15): 3899-3908.
78. Bellavance MA, Poirier MB, Fortin D. Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010;395(1-2):251-259.
79. Cheng Y, Morshed R, Cheng SH, et al. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small. 2013;9(24):4123-4129.
80. Cheng Z, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903-910.
81. Cheng Y, Doane TL, Chuang CH, et al. Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy. Small. 2014;10(9):1799-1804.
82. Thomas CR, Ferris DP, Lee JH, et al. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc. 2010;132(31): 10623-10625.
83. Rapoport NY, Kennedy AM, Shea JE, et al. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release. 2009;138(3):268-276.
84. Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5(209):209ra152.
85. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
86. Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 2011;29(27):3611-3619.
87. Westphal M, Yla-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(9):823-833.
88. Castro MG, Lowenstein PR. Neuro-oncology: The long and winding road-gene therapy for glioma. Nat Rev Neurol. 2013;9(11): 609-610.
89. Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med. 2010;10(50):24-28.
90. Ostertag D, Amundson KK, Lopez Espinoza F, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012;14(2):145-159.
91. Altaner C, Altanerova V, Cihova M, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer. 2014;134(6):1458-1465.
92. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009; 69(23):8932-8940.
93. Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014;16(3):334-351.
94. Guan YQ, Zheng Z, Huang Z, et al. Powerful inner/outer controlled multi-target magnetic nanoparticle drug carrier prepared by liquid photo-immobilization. Sci Rep. 2014;4:1-9.
95. Ma L, Zou XJ, Chen W. A New X-Ray Activated Nanoparticle Photosensitizer for Cancer Treatment. J Biomed Nanotechnol. 2014;10(8):1501-1508.